Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference

Rhea-AI Summary

Apyx Medical (NASDAQ:APYX) said management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL. CEO Charlie Goodwin and CFO Matt Hill will take part in a fireside chat at 8:25am ET and hold investor meetings throughout the day.

The fireside chat will be available via live webcast, with a replay posted in the Events section of Apyx Medical’s Investor Relations website.

Key Figures

Conference date: March 11, 2026 Fireside chat time: 8:25am ET Supporting clinical documents: More than 90 +5 more

8 metrics

Conference date March 11, 2026 Citizens Life Sciences Conference participation

Fireside chat time 8:25am ET Scheduled time for management fireside chat

Supporting clinical documents More than 90 Clinical documents supporting Renuvion and J-Plasma effectiveness

Current share price $3.84 Price before conference participation news

52-week high $4.50 Upper end of 52-week trading range

52-week low $0.7554 Lower end of 52-week trading range

Price vs 52-week low 408.34% Price appreciation from 52-week low to $3.84

Market capitalization $152,630,194 Equity value prior to conference news

Market Reality Check

Price: $3.92 Vol: Volume 127,642 is below t...

normal vol

$3.92 Last Close

Volume Volume 127,642 is below the 20-day average of 142,791 (relative volume 0.89). normal

Technical Price at $3.84 is trading above the 200-day MA of $2.73.

Peers on Argus

Momentum scanner flagged 2 peers (ICCM, BDMD) moving down with median move about...

2 Down

Momentum scanner flagged 2 peers (ICCM, BDMD) moving down with median move about -1.8%, indicating broader sector dynamics, though no same-day peer news was recorded.

Historical Context

5 past events · Latest: Jan 29 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 29	Conference participation	Neutral	+1.0%	Management participation at BTIG MedTech and related conference visibility.
Jan 12	Prelim revenue update	Positive	+14.9%	Strong Q4 and 2025 revenue growth led by Surgical Aesthetics segment.
Dec 03	International approval/launch	Positive	-1.7%	MFDS approval and launch of Apyx One for cosmetic procedures in South Korea.
Nov 18	Equity offering priced	Negative	-5.5%	Pricing of $10M common stock offering at $3.62 per share under shelf.
Nov 17	Offering proposed	Negative	+3.3%	Announcement of proposed public offering from existing S-3 registration.

Pattern Detected

Recent news shows mixed reactions: positive revenue and financing updates often aligned with price moves, while some strategic/expansion news saw divergent reactions.

Recent Company History

Over the last few months, Apyx issued several updates, including preliminary Q4 and full-year 2025 revenue with strong growth and a $10.0M equity offering priced at $3.62 per share on Nov 18, 2025. International expansion continued with approval and launch of Apyx One in South Korea, targeting a cosmetic surgery market projected from $1.7B in 2024 to $3.9B by 2033. Management also increased conference visibility, similar to today’s participation notice, highlighting Renuvion, J-Plasma, and the FDA-cleared AYON platform.

Market Pulse Summary

This announcement highlights Apyx Medical’s participation in an investor-focused life sciences confe...

Analysis

This announcement highlights Apyx Medical’s participation in an investor-focused life sciences conference, with management presenting at 8:25am ET on March 11, 2026 and holding one-on-one meetings. It reinforces the company’s positioning in surgical aesthetics, including Renuvion, J-Plasma, and the FDA-cleared AYON system, supported by more than 90 clinical documents. Investors may watch for subsequent updates on commercial traction, especially following recent revenue growth and international expansion milestones.

Key Terms

helium plasma platform technology, body contouring system, electrosurgical, oem agreements, +1 more

5 terms

helium plasma platform technology medical

"including its Helium Plasma Platform Technology products marketed and sold as Renuvion"

A helium plasma platform uses a stream of ionized helium gas energized by radiofrequency energy to heat, cut or seal human tissue during surgical and aesthetic procedures. Think of it as a focused, high‑heat tool that lets clinicians tighten skin, remove tissue, or control bleeding with minimal cutting—similar to a precision blowtorch compared with a scalpel. Investors care because the technology’s safety profile, regulatory approvals, and adoption by doctors drive device sales, recurring disposable use and potential market growth.

body contouring system medical

"the AYON Body Contouring System™ in the cosmetic surgery market"

A body contouring system is a medical or cosmetic device that reshapes or firms areas of the body by reducing fat, tightening skin, or remodeling tissue using technologies such as lasers, ultrasound, radiofrequency, or cooling. Investors care because these devices drive sales, recurring treatment revenue, and potential margins tied to consumables and maintenance, and their commercial value hinges on safety, regulatory approvals, and patient demand—think of the system as a specialized tool used in aesthetic procedures that must meet medical standards.

electrosurgical medical

"It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities"

Electrosurgical describes tools and procedures that use controlled electric current to cut, seal, or stop bleeding in body tissues during medical procedures, similar to using a heated knife or a precise spark instead of a scalpel. For investors, electrosurgical products matter because they drive sales, device adoption, regulatory reviews, and liability risk in the surgical devices market—factors that affect revenue, profit margins, and company valuations.

oem agreements financial

"through OEM agreements with other medical device manufacturers"

OEM agreements are contracts where one company makes products or components that another company sells under its own brand, like a bakery baking cakes that a café sells with the café’s name. For investors, these deals matter because they influence cost structure, product quality, supply reliability and how much control a brand has over manufacturing; strong OEM partnerships can speed growth but can also create dependence on outside suppliers.

fda-cleared regulatory

"The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. Not financial advice.

CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System™ (AYON), today announced that management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL.

Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Wednesday, March 11, 2026, at 8:25am ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via live webcast here, and a replay will be available on the Events section of Apyx Medical’s Investor Relations website.

About Apyx Medical Corporation:

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion^® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma^® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com  

FAQ

When will Apyx Medical (APYX) present at The Citizens Life Sciences Conference in 2026?

Apyx Medical will present on Wednesday, March 11, 2026 at 8:25am ET. According to the company, CEO Charlie Goodwin and CFO Matt Hill will appear in a fireside chat and conduct one-on-one investor meetings the same day.

How can investors watch the Apyx Medical (APYX) March 11, 2026 fireside chat webcast?

Investors can watch the live webcast via the company’s investor webcast link provided for the event. According to the company, a replay will be posted in the Events section of Apyx Medical’s Investor Relations website after the presentation.

Who from Apyx Medical (APYX) will speak at the March 11, 2026 conference?

Charlie Goodwin, President and CEO, and Matt Hill, CFO, will speak at the event. According to the company, they will participate in a fireside chat at 8:25am ET and hold one-on-one investor meetings throughout March 11, 2026.

What topics will Apyx Medical (APYX) likely cover at the March 11, 2026 fireside chat?

The event will cover recent company developments and strategic updates for investors. According to the company, management’s session aims to discuss Apyx Medical’s products, clinical support, and investor engagement during the March 11, 2026 fireside chat.

Where will the replay of Apyx Medical’s (APYX) March 11, 2026 presentation be available?

The replay will be available in the Events section of Apyx Medical’s Investor Relations website. According to the company, investors can access the recorded fireside chat and related materials after the live March 11, 2026 presentation.